Vivanza Biosciences Publishes FY26 Financial Results Advert
Vivanza Biosciences Limited published an advertisement for its audited FY26 financial results in newspapers on May 9, 2026, as per SEBI regulations. The company achieved a turnaround with a standalone net profit of ₹37.50 lacs and consolidated net profit of ₹39.44 lacs, alongside a significant surge in revenue to ₹11,223.10 lacs on a standalone basis.
*this image is generated using AI for illustrative purposes only.
Vivanza Biosciences Limited has intimated BSE Limited regarding the publication of its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. In accordance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published an advertisement containing the extract of these results in an English daily newspaper (Indian Express) and a Gujarati daily newspaper (Financial Express) on May 9, 2026. The intimation was signed by Jayendra Mehta, Managing Director, and confirmed that the results were approved by the Board of Directors on May 7, 2026.
Financial Performance Overview
The Board meeting held on May 7, 2026, approved the audited financial results, marking a significant turnaround in the company's performance. Vivanza Biosciences reported a standalone net profit of ₹37.50 lacs for the full fiscal year FY26, reversing the net loss of ₹69.51 lacs recorded in the previous fiscal year. Revenue from operations surged to ₹11,223.10 lacs, a substantial increase from ₹294.28 lacs in FY25. For the quarter ended March 31, 2026, the company reported a net loss of ₹26.61 lacs, an improvement compared to the net loss of ₹96.54 lacs in the same quarter of the previous year.
On a consolidated basis, the group reported a net profit of ₹39.44 lacs for FY26, compared to a net loss of ₹67.41 lacs in FY25. Consolidated revenue from operations rose to ₹11,591.06 lacs from ₹742.33 lacs in the prior year. The consolidated net loss for Q4 FY26 stood at ₹45.08 lacs, compared to a net loss of ₹99.81 lacs in the corresponding quarter of the previous year.
| Metric | FY26 (Audited) | FY25 (Audited) |
|---|---|---|
| Standalone Revenue | 11,223.10 | 294.28 |
| Standalone Net Profit | 37.50 | -69.51 |
| Consolidated Revenue | 11,591.06 | 742.33 |
| Consolidated Net Profit | 39.44 | -67.41 |
Regulatory Compliance
The company has ensured compliance with SEBI regulations by disseminating the financial results through newspaper publications. The results, along with the Auditor's Report, have also been posted on the company's official website. The statutory audit was carried out by SHIVAM SONI & Co., Chartered Accountants, and the Audit Report contains no observations that impact the results for the quarter or year ended March 31, 2026. The communication regarding the advertisement publication was filed with BSE Limited under Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Historical Stock Returns for Vivanza Biosciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +6.01% | -3.00% | -4.90% | -25.67% | -7.18% | -69.40% |
Given the sharp revenue surge from ₹294 lacs to ₹11,223 lacs in FY26 but a Q4 revenue drop to ₹574 lacs from Q3's ₹4,493 lacs, is Vivanza Biosciences' revenue growth sustainable or driven by one-time orders?
With current borrowings rising to ₹662 lacs standalone and cash equivalents critically low at ₹1.78 lacs, how will Vivanza manage its liquidity and working capital needs in FY27?
How might the simultaneous resignation of a Non-Executive Director and the Company Secretary & Compliance Officer impact Vivanza's corporate governance standards and investor confidence going forward?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
